Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma
Abstract Background Use of statins is associated with a reduced risk of hepatocellular carcinoma (HCC). However, the effect of statin use on HCC recurrence is unclear. This study aimed to evaluate the effect of statin use on recurrence after curative resection among patients with HCC. Methods We ret...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-021-07796-7 |
| _version_ | 1830271754788929536 |
|---|---|
| author | Shih-Yu Yang Chih-Chi Wang Kuang-Den Chen Yueh-Wei Liu Chih-Che Lin Ching-Hui Chuang Yu-Chieh Tsai Chih-Chien Yao Yi-Hao Yen Chang-Chun Hsiao Tsung-Hui Hu Ming-Chao Tsai |
| author_facet | Shih-Yu Yang Chih-Chi Wang Kuang-Den Chen Yueh-Wei Liu Chih-Che Lin Ching-Hui Chuang Yu-Chieh Tsai Chih-Chien Yao Yi-Hao Yen Chang-Chun Hsiao Tsung-Hui Hu Ming-Chao Tsai |
| author_sort | Shih-Yu Yang |
| collection | DOAJ |
| description | Abstract Background Use of statins is associated with a reduced risk of hepatocellular carcinoma (HCC). However, the effect of statin use on HCC recurrence is unclear. This study aimed to evaluate the effect of statin use on recurrence after curative resection among patients with HCC. Methods We retrospectively assessed 820 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A HCC who underwent primary resection between January 2001 and June 2016 at Kaohsiung Chang Gung Memorial Hospital. Exposure to statins was defined as use of a statin for at least 3 months before HCC recurrence. Factors that influenced overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards models. Results Of the 820 patients, 46 (5.6%) used statins (statin group) and 774 (94.4%) did not (non-statin group). During the mean follow-up of 76.5 months, 440 (53.7%) patients experienced recurrence and 146 (17.8%) patients died. The cumulative incidence of HCC recurrence was significantly lower in the statin group than the non-statin group (p = 0.001); OS was not significantly different between groups. In multivariate analysis, age (hazard ratio [HR]: 1.291; p = 0.010), liver cirrhosis (HR: 1.743; p < 0.001), diabetes (HR:1.418; p = 0.001), number of tumors (HR: 1.750; p < 0.001), tumor size (HR: 1.406; p = 0.004) and vascular invasion (HR: 1.659; p < 0.001) were independent risk factors for HCC recurrence, whereas statin use (HR: 0.354; p < 0.001) and antiviral therapy (HR: 0.613; p < 0.001) significantly reduced the risk of HCC recurrence. The statin group still had lower RFS than the non-statin group after one-to-four propensity score matching. Conclusion Statins may exert a chemo-preventive effect on HCC recurrence after curative resection. |
| first_indexed | 2024-12-18T23:12:16Z |
| format | Article |
| id | doaj.art-3c22d97a32e943d9bc2c3b4a86b9f980 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-18T23:12:16Z |
| publishDate | 2021-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-3c22d97a32e943d9bc2c3b4a86b9f9802022-12-21T20:48:19ZengBMCBMC Cancer1471-24072021-01-0121111310.1186/s12885-021-07796-7Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinomaShih-Yu Yang0Chih-Chi Wang1Kuang-Den Chen2Yueh-Wei Liu3Chih-Che Lin4Ching-Hui Chuang5Yu-Chieh Tsai6Chih-Chien Yao7Yi-Hao Yen8Chang-Chun Hsiao9Tsung-Hui Hu10Ming-Chao Tsai11Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineLiver Transplantation Center and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineCenter for Translational Research in Biomedical Sciences, Liver Transplantation Program and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineLiver Transplantation Center and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineLiver Transplantation Center and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineHead Nurse, Department of Nursing, Kaohsiung Chang Gung Memorial HospitalDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung UniversityDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineAbstract Background Use of statins is associated with a reduced risk of hepatocellular carcinoma (HCC). However, the effect of statin use on HCC recurrence is unclear. This study aimed to evaluate the effect of statin use on recurrence after curative resection among patients with HCC. Methods We retrospectively assessed 820 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A HCC who underwent primary resection between January 2001 and June 2016 at Kaohsiung Chang Gung Memorial Hospital. Exposure to statins was defined as use of a statin for at least 3 months before HCC recurrence. Factors that influenced overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards models. Results Of the 820 patients, 46 (5.6%) used statins (statin group) and 774 (94.4%) did not (non-statin group). During the mean follow-up of 76.5 months, 440 (53.7%) patients experienced recurrence and 146 (17.8%) patients died. The cumulative incidence of HCC recurrence was significantly lower in the statin group than the non-statin group (p = 0.001); OS was not significantly different between groups. In multivariate analysis, age (hazard ratio [HR]: 1.291; p = 0.010), liver cirrhosis (HR: 1.743; p < 0.001), diabetes (HR:1.418; p = 0.001), number of tumors (HR: 1.750; p < 0.001), tumor size (HR: 1.406; p = 0.004) and vascular invasion (HR: 1.659; p < 0.001) were independent risk factors for HCC recurrence, whereas statin use (HR: 0.354; p < 0.001) and antiviral therapy (HR: 0.613; p < 0.001) significantly reduced the risk of HCC recurrence. The statin group still had lower RFS than the non-statin group after one-to-four propensity score matching. Conclusion Statins may exert a chemo-preventive effect on HCC recurrence after curative resection.https://doi.org/10.1186/s12885-021-07796-7Hepatocellular carcinomaStatinResectionRecurrence |
| spellingShingle | Shih-Yu Yang Chih-Chi Wang Kuang-Den Chen Yueh-Wei Liu Chih-Che Lin Ching-Hui Chuang Yu-Chieh Tsai Chih-Chien Yao Yi-Hao Yen Chang-Chun Hsiao Tsung-Hui Hu Ming-Chao Tsai Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma BMC Cancer Hepatocellular carcinoma Statin Resection Recurrence |
| title | Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma |
| title_full | Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma |
| title_fullStr | Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma |
| title_full_unstemmed | Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma |
| title_short | Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma |
| title_sort | statin use is associated with a lower risk of recurrence after curative resection in bclc stage 0 a hepatocellular carcinoma |
| topic | Hepatocellular carcinoma Statin Resection Recurrence |
| url | https://doi.org/10.1186/s12885-021-07796-7 |
| work_keys_str_mv | AT shihyuyang statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT chihchiwang statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT kuangdenchen statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT yuehweiliu statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT chihchelin statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT chinghuichuang statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT yuchiehtsai statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT chihchienyao statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT yihaoyen statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT changchunhsiao statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT tsunghuihu statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma AT mingchaotsai statinuseisassociatedwithalowerriskofrecurrenceaftercurativeresectioninbclcstage0ahepatocellularcarcinoma |